SMT202100066T1 - Proteine di fusione dr5-leganti multivalenti e multispecifiche - Google Patents

Proteine di fusione dr5-leganti multivalenti e multispecifiche

Info

Publication number: SMT202100066T1
Authority: SM; San Marino
Prior art keywords: multispecific; multivalent; fusion proteins; binding fusion; binding
Prior art date: 2015-07-16

Application number

SM20210066T

Other languages

English (en)

Inventor

Quinn Deveraux

John C Timmer

Kyle S Jones

Amir S Razai

Abrahim Hussain

Katelyn M Willis

Brendan P Eckelman

Original Assignee

Inhibrx Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-07-16

Filing date

2016-07-18

Publication date

2021-03-15

2016-07-18 Application filed by Inhibrx Inc filed Critical Inhibrx Inc

2021-03-15 Publication of SMT202100066T1 publication Critical patent/SMT202100066T1/it

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001138—Tumor necrosis factors [TNF] or CD70
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Oncology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Zoology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

SM20210066T 2015-07-16 2016-07-18 Proteine di fusione dr5-leganti multivalenti e multispecifiche SMT202100066T1 (it)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201562193309P	2015-07-16	2015-07-16
EP16825315.1A EP3322734B1 (en)	2015-07-16	2016-07-18	Multivalent and multispecific dr5-binding fusion proteins
PCT/US2016/042862 WO2017011837A2 (en)	2015-07-16	2016-07-18	Multivalent and multispecific dr5-binding fusion proteins

Publications (1)

Publication Number	Publication Date
SMT202100066T1 true SMT202100066T1 (it)	2021-03-15

Family

ID=57757772

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SM20210066T SMT202100066T1 (it)	2015-07-16	2016-07-18	Proteine di fusione dr5-leganti multivalenti e multispecifiche

Country Status (26)

Country	Link
US (4)	US10308720B2 (it)
EP (2)	EP3322734B1 (it)
JP (4)	JP6807606B2 (it)
KR (2)	KR20250017305A (it)
CN (2)	CN107922491B (it)
AU (2)	AU2016291701B2 (it)
BR (1)	BR112018000584A2 (it)
CA (1)	CA2991634A1 (it)
CY (1)	CY1123615T1 (it)
DK (1)	DK3322734T3 (it)
ES (1)	ES2833773T3 (it)
HR (1)	HRP20201785T1 (it)
HU (1)	HUE051896T2 (it)
IL (3)	IL307994A (it)
LT (1)	LT3322734T (it)
MX (2)	MX2018000523A (it)
NZ (1)	NZ777930A (it)
PL (1)	PL3322734T3 (it)
PT (1)	PT3322734T (it)
RS (1)	RS61062B1 (it)
RU (2)	RU2021111382A (it)
SG (1)	SG10201912410TA (it)
SI (1)	SI3322734T1 (it)
SM (1)	SMT202100066T1 (it)
WO (1)	WO2017011837A2 (it)
ZA (1)	ZA201800238B (it)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG11201909160WA (en)	2017-04-11	2019-10-30	Inhibrx Inc	Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
CN111819198A (zh) *	2017-12-28	2020-10-23	尤利乌斯·马克西米利安维尔茨堡大学	具有非FcγR依赖性激动活性的肿瘤坏死因子(TNF)受体超家族(TNFRSF)受体-激活抗体融合蛋白(具有非FcγR依赖性激动活性的TNFRSF受体-激活抗体融合蛋白；TRAAFFIAA)
CN110305210B (zh) *	2018-03-27	2023-02-28	信达生物制药(苏州)有限公司	新型抗体分子、其制备方法及其用途
CN112218686A (zh)	2018-04-11	2021-01-12	印希比股份有限公司	具有受限cd3结合的多特异性多肽构建体以及相关方法和用途
WO2020047705A1 (zh) *	2018-09-03	2020-03-12	安菲尼生命科技有限公司	Dr5单域抗体及其用途
CN115175736A (zh) *	2019-10-01	2022-10-11	艾普西洛根有限公司	杂交抗体
TW202245839A (zh) *	2021-02-19	2022-12-01	美商英伊布里克斯公司	Dr5結合多肽之調配物
CN119365489A (zh) *	2022-04-08	2025-01-24	印希比生物科学有限公司	Dr5激动剂与plk1抑制剂或cdk抑制剂组合疗法
AU2023275703A1 (en) *	2022-05-23	2024-11-21	Inhibrx Biosciences, Inc.	Dr5 agonist and iap antagonist combination therapy
CN117285644A (zh) *	2022-06-16	2023-12-26	清华大学	一种相变调节元件及其用途
WO2024069180A2 (en)	2022-09-28	2024-04-04	LiliumX Ltd.	Multivalent proteins and screening methods
WO2025006846A2 (en) *	2023-06-29	2025-01-02	Odyssey Therapeutics, Inc.	Anti-trailr2 antigen-binding proteins and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0563296B1 (en)	1990-12-20	1999-03-17	Ixsys, Inc.	Optimization of binding proteins
US20020147140A1 (en) *	2000-01-31	2002-10-10	Rosen Craig A.	Nucleic acids, proteins, and antibodies
KR20070010046A (ko)	2004-04-06	2007-01-19	제넨테크, 인크.	Ｄｒ5 항체 및 그의 용도
MX2007008017A (es)	2004-12-31	2007-09-12	Genentech Inc	Polipeptidos que se ligan a br3 y usos de los mismos.
RU2007135030A (ru)	2005-02-24	2009-03-27	Симайнз, Инк. (Us)	Композиции и способы классификации биологических образцов
US8124076B2 (en)	2005-08-18	2012-02-28	Ramot At Tel Aviv University Ltd.	Single chain antibodies against β-amyloid peptide
KR20080077261A (ko)	2005-12-06	2008-08-21	도만티스 리미티드	Ｅｇｆｒ 및/또는 ｖｅｇｆ에 대해 결합 특이성이 있는리간드 및 그의 사용 방법
DK1987178T3 (en)	2006-02-20	2015-04-20	Phylogica Ltd	Process for the construction and screening of peptide structure libraries
JP2008133206A (ja)	2006-11-28	2008-06-12	Yokohama City Univ	緑膿菌に対して感染防御能を誘導できる医薬組成物
NZ586357A (en)	2007-11-30	2012-10-26	Kalobios Pharmaceuticals Inc	Antibodies to the pcrv antigen of pseudomonas aeruginosa
PL2285408T3 (pl) *	2008-06-05	2019-05-31	Ablynx Nv	Sekwencje aminokwasowe skierowane przeciwko białkom otoczki wirusa i polipeptydy je zawierające do leczenia chorób wirusowych
US20110166076A1 (en) *	2008-09-10	2011-07-07	Bac Ip B.V.	Antigen-binding proteins that inhibit superantigens for the treatment of skin diseases
WO2010107778A1 (en)	2009-03-18	2010-09-23	Wake Forest University Health Sciences	Flagellin fusion proteins and use thereof to induce immune responses against pseudomonas aeruginosa
WO2010115141A2 (en)	2009-04-02	2010-10-07	New York University	System and uses for generating databases of protein secondary structures involved in inter-chain protein interactions
CN101717775B (zh) *	2009-11-13	2012-01-04	厦门大学	抗人死亡受体5的单链抗体基因
WO2011073180A1 (en)	2009-12-14	2011-06-23	Ablynx N.V.	Single variable domain antibodies against ox40l, constructs and therapeutic use
US9120855B2 (en) *	2010-02-10	2015-09-01	Novartis Ag	Biologic compounds directed against death receptor 5
WO2011134060A1 (en)	2010-04-27	2011-11-03	National Research Council Of Canada	Anti-icam-1 single domain antibody and uses thereof
US8877899B2 (en) *	2010-09-27	2014-11-04	Morphosys Ag	Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multipe myeloma and NHL
WO2012055030A1 (en)	2010-10-25	2012-05-03	National Research Council Of Canada	Clostridium difficile-specific antibodies and uses thereof
AU2011348396A1 (en)	2010-12-23	2013-07-04	Valneva Austria Gmbh	OprF/I agents and their use in hospitalized and other patients
AU2012296961B2 (en)	2011-08-17	2017-02-16	Glaxo Group Limited	Modified proteins and peptides
SMT202000091T1 (it) *	2011-10-13	2020-05-08	Bristol Myers Squibb Co	Polipeptidi anticorpali che antagonizzano cd40l
CN103906533A (zh)	2011-11-07	2014-07-02	米迪缪尼有限公司	多特异性和多价结合蛋白及其用途
EP2794661B1 (en)	2011-12-20	2019-03-06	Adaerata, Limited Partnership	Single domain antibodies as inhibitors of pcsk9
RU2014139911A (ru)	2012-03-02	2016-04-20	Аблинкс Нв	Антитела из одиночных вариабельных доменов, связывающие белок pcrv pseudomonas aeruginosa
US20130302250A1 (en)	2012-05-07	2013-11-14	The University Court Of The University Of Aberdeen	Single domain binding molecule
EP2684896A1 (en) *	2012-07-09	2014-01-15	International-Drug-Development-Biotech	Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
CN104781277A (zh)	2012-09-13	2015-07-15	诺华股份有限公司	具有末端修饰的抗原结合分子
CN104995209A (zh)	2012-11-06	2015-10-21	米迪缪尼有限公司	使用抗假单胞菌Psl和PcrV结合分子的联合治疗
CN102924600B (zh) *	2012-11-14	2013-10-30	河南大学	死亡受体5激动性多价抗体及其在制备抗肿瘤药物中的应用
WO2014111550A1 (en)	2013-01-17	2014-07-24	Glaxosmithkline Intellectual Property Development Limited	Modified anti-serum albumin binding proteins
US9862777B2 (en)	2013-05-28	2018-01-09	Vib Vzw	Single domain antibodies against SOD1 and their use in medicine
JP6176683B2 (ja) *	2014-01-10	2017-08-09	学校法人帝京平成大学	組換え偏性嫌気性グラム陽性菌

2016
- 2016-07-18 SM SM20210066T patent/SMT202100066T1/it unknown
- 2016-07-18 DK DK16825315.1T patent/DK3322734T3/da active
- 2016-07-18 RS RS20201315A patent/RS61062B1/sr unknown
- 2016-07-18 JP JP2018501345A patent/JP6807606B2/ja active Active
- 2016-07-18 RU RU2021111382A patent/RU2021111382A/ru unknown
- 2016-07-18 HR HRP20201785TT patent/HRP20201785T1/hr unknown
- 2016-07-18 IL IL307994A patent/IL307994A/en unknown
- 2016-07-18 BR BR112018000584A patent/BR112018000584A2/pt active Search and Examination
- 2016-07-18 ES ES16825315T patent/ES2833773T3/es active Active
- 2016-07-18 SG SG10201912410TA patent/SG10201912410TA/en unknown
- 2016-07-18 KR KR1020257002277A patent/KR20250017305A/ko active Pending
- 2016-07-18 US US15/213,296 patent/US10308720B2/en active Active
- 2016-07-18 PL PL16825315T patent/PL3322734T3/pl unknown
- 2016-07-18 NZ NZ777930A patent/NZ777930A/en unknown
- 2016-07-18 WO PCT/US2016/042862 patent/WO2017011837A2/en active IP Right Grant
- 2016-07-18 SI SI201631005T patent/SI3322734T1/sl unknown
- 2016-07-18 CN CN201680041274.2A patent/CN107922491B/zh active Active
- 2016-07-18 MX MX2018000523A patent/MX2018000523A/es unknown
- 2016-07-18 LT LTEP16825315.1T patent/LT3322734T/lt unknown
- 2016-07-18 EP EP16825315.1A patent/EP3322734B1/en active Active
- 2016-07-18 HU HUE16825315A patent/HUE051896T2/hu unknown
- 2016-07-18 AU AU2016291701A patent/AU2016291701B2/en active Active
- 2016-07-18 RU RU2018102803A patent/RU2748620C2/ru active
- 2016-07-18 EP EP20189995.2A patent/EP3798232A1/en active Pending
- 2016-07-18 CA CA2991634A patent/CA2991634A1/en active Pending
- 2016-07-18 KR KR1020187000975A patent/KR102760380B1/ko active Active
- 2016-07-18 PT PT168253151T patent/PT3322734T/pt unknown
- 2016-07-18 CN CN202111039963.9A patent/CN114106178A/zh active Pending
- 2016-07-18 IL IL292037A patent/IL292037A/en unknown
2018
- 2018-01-07 IL IL256772A patent/IL256772B/en unknown
- 2018-01-12 MX MX2023002379A patent/MX2023002379A/es unknown
- 2018-01-12 ZA ZA2018/00238A patent/ZA201800238B/en unknown
2019
- 2019-04-18 US US16/387,754 patent/US11117973B2/en active Active
2020
- 2020-11-16 CY CY20201101085T patent/CY1123615T1/el unknown
- 2020-11-26 JP JP2020196358A patent/JP7244938B2/ja active Active
2021
- 2021-08-05 US US17/394,900 patent/US11976126B2/en active Active
2022
- 2022-11-30 JP JP2022191038A patent/JP2023022214A/ja active Pending
- 2022-12-21 AU AU2022291498A patent/AU2022291498A1/en active Pending
2024
- 2024-04-04 US US18/626,699 patent/US20240376220A1/en active Pending
2025
- 2025-03-03 JP JP2025032594A patent/JP2025084923A/ja active Pending

Also Published As

Publication number	Publication date
EP3322734A4 (en)	2019-04-17
EP3798232A1 (en)	2021-03-31
AU2016291701A1 (en)	2018-01-25
JP2021046414A (ja)	2021-03-25
CA2991634A1 (en)	2017-01-19
US11117973B2 (en)	2021-09-14
HUE051896T2 (hu)	2021-03-29
US20170015753A1 (en)	2017-01-19
SG10201912410TA (en)	2020-02-27
AU2022291498A1 (en)	2023-02-02
US20190309083A1 (en)	2019-10-10
RU2748620C2 (ru)	2021-05-28
JP2018522888A (ja)	2018-08-16
NZ738850A (en)	2024-11-29
US10308720B2 (en)	2019-06-04
ZA201800238B (en)	2021-07-28
IL256772A (en)	2018-03-29
CN107922491A (zh)	2018-04-17
MX2023002379A (es)	2023-03-21
KR20180030518A (ko)	2018-03-23
WO2017011837A3 (en)	2017-03-02
KR102760380B1 (ko)	2025-01-31
BR112018000584A2 (pt)	2018-09-11
JP6807606B2 (ja)	2021-01-06
DK3322734T3 (da)	2020-10-26
KR20250017305A (ko)	2025-02-04
IL307994A (en)	2023-12-01
RS61062B1 (sr)	2020-12-31
CN114106178A (zh)	2022-03-01
US20220064318A1 (en)	2022-03-03
US11976126B2 (en)	2024-05-07
ES2833773T3 (es)	2021-06-15
RU2021111382A (ru)	2021-05-21
NZ777930A (en)	2025-05-02
EP3322734A2 (en)	2018-05-23
IL292037A (en)	2022-06-01
US20240376220A1 (en)	2024-11-14
IL256772B (en)	2022-05-01
JP2023022214A (ja)	2023-02-14
PL3322734T3 (pl)	2021-05-04
RU2018102803A3 (it)	2019-12-27
RU2018102803A (ru)	2019-08-19
LT3322734T (lt)	2021-02-10
MX2018000523A (es)	2018-04-13
SI3322734T1 (sl)	2021-02-26
JP7244938B2 (ja)	2023-03-23
PT3322734T (pt)	2020-11-30
AU2016291701B2 (en)	2022-09-29
WO2017011837A2 (en)	2017-01-19
EP3322734B1 (en)	2020-09-09
HK1254433A1 (en)	2019-07-19
JP2025084923A (ja)	2025-06-03
CN107922491B (zh)	2021-09-28
CY1123615T1 (el)	2022-03-24
HRP20201785T1 (hr)	2021-01-22

Publication	Publication Date	Title
SG10201913807QA (en)	2020-03-30	Multivalent and multispecific gitr-binding fusion proteins
SG10201912405TA (en)	2020-02-27	Multivalent and multispecific 41bb-binding fusion proteins
IL254965A0 (en)	2017-12-31	fusion proteins
ZA201800238B (en)	2021-07-28	Multivalent and multispecific dr5-binding fusion proteins
GB201509413D0 (en)	2015-07-15	Fusion protein
GB201509062D0 (en)	2015-07-08	OX40L fusion proteins and uses thereof
IL246355A0 (en)	2016-08-31	p97–ids fused proteins
GB201504691D0 (en)	2015-05-06	Fusion protein
GB201515745D0 (en)	2015-10-21	Proteins
GB201511787D0 (en)	2015-08-19	Proteins
ZA201606327B (en)	2019-01-30	Uti fusion proteins
GB201513033D0 (en)	2015-09-09	Proteins
EP3237452A4 (en)	2018-12-05	Fusion proteins and methods thereof
ZA201801394B (en)	2020-07-29	Fusion protein
SG11201606501PA (en)	2016-09-29	Nanobody-fluorescent protein fusion
GB201602850D0 (en)	2016-04-06	Fusion proteins
HK1255651A1 (en)	2019-08-23	Multivalent and multispecific gitr-binding fusion proteins
HK1261708A1 (en)	2020-01-03	Multivalent and multispecific ox40-binding fusion proteins
HK1261500A1 (en)	2020-01-03	Multivalent and multispecific 41bb-binding fusion proteins
GB201503778D0 (en)	2015-04-22	Proteins